S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,012.70 +0.68% CRUDE 82.49 +4.48% BITCOIN 64,570.77 +1.05%
Next Bullish Trade
Sign in
ABT

Abbott Laboratories NYQ · ABT

$100.68 +1.85 (+1.87%)
Blow-off · +2.37σ Hot zone Grade C
+ Compare Open in Sniper

Price chart

Timeframe
Range
Fundamentals · free Click ▲ earnings markers (daily) for the day's move

Loading…

Latest bar · ABT

Momentum reads · latest daily bar
Last
$100.68
+1.85 (+1.87%)
Mkt cap
$175.4B
Healthcare
RSI(14)
66.5
neutral
Stochastic %K
61.4
neutral
MFI(14)
55.6
neutral
ADX(14)
22.1
building

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $11.2B $1.1B $1.3B $0.9B 9.6% 12.0%
2025-12-31 $11.5B $1.8B $2.3B $2.6B 15.5% 19.6%
2025-09-30 $11.4B $1.6B $2.1B $2.3B 14.5% 18.1%
2025-06-30 $11.1B $1.8B $2.1B $1.5B 16.0% 18.4%
2025-03-31 $10.4B $1.3B $1.7B $0.9B 12.8% 16.3%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare ABT vs peers

Line ABT up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing ABT no peers yet — add up to 4 below
Sector peers + LLY + UNH + JNJ + MRK + ABBV + PFE
Popular + AAPL + MSFT + NVDA + AMZN + GOOG + META + TSLA + AVGO
Matchups NVDA · AMD · AVGO · SMCI · MU AAPL · MSFT · GOOG · META · AMZN JPM · GS · MS · BAC · C TSLA · RIVN · LCID · GM · F XOM · CVX · OXY · COP

Add tickers to compare with ABT

~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.

Earnings replay · last 20 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

DateEPS actual EPS estSurprise Next-day
2026-07-16 1.31 1.28 +2.6% +1.9%
2026-04-16 1.15 1.15 +0.3% +1.4%
2026-01-22 1.50 1.49 +0.3% -1.1%
2025-10-15 1.30 1.30 +0.1% -1.4%
2025-07-17 1.26 1.26 +0.3% +2.6%
2025-04-16 1.09 1.07 +1.7% +1.0%
2025-01-22 1.34 1.34 -0.2% +4.6%
2024-10-16 1.21 1.20 +0.8% +0.1%
2024-07-18 1.14 1.10 +3.2% +2.0%
2024-04-17 0.98 0.95 +2.8% -0.6%
2024-01-24 1.19 1.19 +0.0% +1.5%
2023-10-18 1.14 1.10 +3.7% -0.1%
2023-07-20 1.08 1.05 +2.9% +2.2%
2023-04-19 1.03 0.99 +4.3% -1.7%
2023-01-25 1.03 0.94 +9.7% +0.1%
2022-10-19 1.15 0.94 +22.9% -3.0%
2022-07-20 1.43 1.14 +25.3% +2.3%
2022-04-20 1.73 1.46 +18.1% +0.6%
2022-01-26 1.32 1.21 +9.5% +0.3%
2021-10-20 1.40 0.95 +47.9% +1.4%

Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
LLY $1,051B 41.8 26.3 14.6 30.1 33.8 82.8% 55.5% 169.9% 0.87%
UNH $387B 32.1 19.2 0.9 17.7 4.0 19.5% 0.4% 61.5% 5.88%
JNJ $609B 29.3 19.7 6.2 18.4 7.5 68.1% 6.6% -1.0% —
MRK $315B 36.0 13.2 4.8 12.1 6.9 76.7% 4.9% — 4.46%
ABBV $450B 124.8 15.6 7.2 17.2 -67.6 72.0% 12.4% -46.2% 4.63%
PFE $143B 19.1 8.8 2.3 7.6 1.6 74.8% 5.4% -10.1% 8.67%
TMO $198B 29.2 19.5 4.4 21.1 3.8 40.9% 6.2% 11.3% 2.79%
ABT ★ $175B 28.2 16.6 3.8 17.1 3.4 56.8% 13.0% -47.5% —

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 35.31%

HolderShares% out
Blackrock Inc. 145,687,458 8.36%
Vanguard Capital Management LLC 112,949,933 6.48%
State Street Corporation 79,575,468 4.57%
Capital Research Global Investors 49,775,362 2.86%
Vanguard Portfolio Management LLC 47,944,891 2.75%
Charles Schwab Investment Management 45,500,055 2.61%
Geode Capital Management, LLC 39,148,795 2.25%
Capital International Investors 37,498,227 2.15%
Morgan Stanley 30,101,596 1.73%
Wellington Management Group, LLP 27,070,518 1.55%

Insider activity · 90d

13 buys / 0 sells · ratio 13.0 · Finnhub

  • Ahuja Nita BUY 450 @ $90.74
  • Gonzalez Patricia Paola BUY 5,963 @ $90.74
  • Morrone Louis H. F 76,574 @ $92.71
  • Roman Michael F BUY 6,746 @ $90.74
  • Stratton John G BUY 14,022 @ $90.74
  • Conroy Kevin T BUY 231 @ $90.74
  • Stratton John G BUY 23,319 @ $86.82
  • Moreland Mary K I 17,159 @ $94.41
  • STARKS DANIEL J BUY 6,751,103 @ $92.65
  • Ahuja Nita BUY 2,286

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low
$92.0
Mean
$118.33333
High
$135.0
Analysts
24
Recommendation distribution · period 2026-07-01
11
14
10
Revision trend (2026-04-01 → 2026-07-01): net 26 → 25 -1 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

FormFiled DescriptionAction
8-K 2026-07-16 8-K view ·
4 2026-07-01 Insider transaction (Form 4) view ·
4 2026-07-01 Insider transaction (Form 4) view ·
4 2026-07-01 Insider transaction (Form 4) view ·
4 2026-07-01 Insider transaction (Form 4) view ·
4 2026-07-01 Insider transaction (Form 4) view ·
4 2026-07-01 Insider transaction (Form 4) view ·
4 2026-06-29 Insider transaction (Form 4) view ·
4 2026-06-18 Insider transaction (Form 4) view ·
4 2026-04-29 Insider transaction (Form 4) view ·
10-Q 2026-04-29 10-Q view ·
4 2026-04-28 Insider transaction (Form 4) view ·
4 2026-04-28 Insider transaction (Form 4) view ·
4 2026-04-28 Insider transaction (Form 4) view ·
4 2026-04-28 Insider transaction (Form 4) view ·
4 2026-04-28 Insider transaction (Form 4) view ·
4 2026-04-28 Insider transaction (Form 4) view ·
4 2026-04-28 Insider transaction (Form 4) view ·
4 2026-04-28 Insider transaction (Form 4) view ·
4 2026-04-28 Insider transaction (Form 4) view ·
4 2026-04-28 Insider transaction (Form 4) view ·
4 2026-04-28 Insider transaction (Form 4) view ·
4 2026-04-28 Insider transaction (Form 4) view ·
4 2026-04-27 Insider transaction (Form 4) view ·
8-K 2026-04-27 FORM 8-K view ·
8-K 2026-04-17 FORM 8-K view ·
8-K 2026-04-16 8-K view ·
4 2026-04-02 Insider transaction (Form 4) view ·
4 2026-04-02 Insider transaction (Form 4) view ·
4 2026-04-02 Insider transaction (Form 4) view ·
4 2026-04-02 Insider transaction (Form 4) view ·
4 2026-04-02 Insider transaction (Form 4) view ·
4 2026-03-25 Insider transaction (Form 4) view ·
8-K 2026-03-23 FORM 8-K view ·
DEF 14A 2026-03-13 DEFINITIVE PROXY STATEMENT view ·
8-K 2026-03-09 FORM 8-K view ·
4 2026-03-03 Insider transaction (Form 4) view ·
4 2026-03-03 Insider transaction (Form 4) view ·
4 2026-03-03 Insider transaction (Form 4) view ·
4 2026-03-03 Insider transaction (Form 4) view ·
4 2026-03-03 Insider transaction (Form 4) view ·
4 2026-03-03 Insider transaction (Form 4) view ·
4 2026-03-03 Insider transaction (Form 4) view ·
4 2026-03-03 Insider transaction (Form 4) view ·
4 2026-03-03 Insider transaction (Form 4) view ·
4 2026-03-03 Insider transaction (Form 4) view ·
4 2026-02-26 Insider transaction (Form 4) view ·
4 2026-02-26 Insider transaction (Form 4) view ·
4 2026-02-26 Insider transaction (Form 4) view ·
4 2026-02-26 Insider transaction (Form 4) view ·
4 2026-02-26 Insider transaction (Form 4) view ·
4 2026-02-26 Insider transaction (Form 4) view ·
4 2026-02-26 Insider transaction (Form 4) view ·
4 2026-02-26 Insider transaction (Form 4) view ·
4 2026-02-26 Insider transaction (Form 4) view ·
4 2026-02-26 Insider transaction (Form 4) view ·
8-K 2026-02-26 FORM 8-K view ·
8-K 2026-02-20 FORM 8-K view ·
10-K 2026-02-20 10-K view ·
4 2026-02-06 Insider transaction (Form 4) view ·

About ABT

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood ga…

Options picks · ABT

ITM + OTM ideas from the latest scan

Loading…

Congress trades · ABT

STOCK Act disclosures

Loading…

SEC filings & insiders · ABT

EDGAR · live

Loading…

Holders · ABT

Institutions & insider activity

Loading…